WTX-124

WTX-124 is a systemically delivered, conditionally activated Interleukin-2 (IL-2) prodrug engineered to remain inactive in the periphery and selectively release fully potent wild-type IL-2 within the tumor microenvironment. This design aims to stimulate antitumor immunity while minimizing the severe toxicities associated with traditional recombinant IL-2 therapy. The molecule is part of Werewolf Therapeutics' INDUKINE platform and is being developed for use as monotherapy or in combination with immune checkpoint inhibitors such as pembrolizumab. In clinical studies, WTX-124 has demonstrated clinical activity and a favorable safety profile in patients with relapsed or refractory solid tumors who have previously received checkpoint inhibitor therapy[3][4][6][7]. Mechanistically, it leverages tumor-associated proteases for activation within tumors, leading to local immune stimulation by expanding effector T cells preferentially over regulatory T cells[7][8].